Real-World Evaluation of Treatment Patterns Among Patients With Chronic-Phase Chronic Myeloid Leukemia (CMLCP) in a Large Community Oncology Setting

被引：0
|
作者：
Zackon, Ira [1 ]
McDermott, Courtney [2 ]
Beeks, April [1 ]
Wentworth, Chuck [1 ]
Guo, Jinhong [1 ]
Jadhav, Kejal [2 ]
Wei, David [2 ]
Damon, Andrea [2 ]
Sadek, Islam [2 ]
Benton, Christopher [3 ]
机构：
[1] Ontada, Boston, MA USA
[2] Novartis, E Hanover, NJ USA
[3] Rocky Mt Canc Ctr, Aurora, CO USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CML; TKI; chronic phase; treatment patterns; real-world data;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-636
引用
收藏
页码：S381 / S381
页数：1
相关论文
共 50 条
  • [31] Real-World Patterns of MRD Testing and Impact on Treatment for Chronic Lymphocytic Leukemia Patients
    Bacchus, Melissa
    Singh-Bulkan, Nivita
    Littleford, Hana E.
    Kim, Joseph
    Martin, Richard L.
    Lacoste, Alix M. B.
    Brimble, Elise
    O'Brien, Conner
    Saltzman, Larry A.
    Greenberger, Lee M.
    Nottke, Amanda
    BLOOD, 2023, 142
  • [32] Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
    Matteo Molica
    Gioia Colafigli
    Emilia Scalzulli
    Danilo Alunni Fegatelli
    Sofia Chiatamone Ranieri
    Lorenzo Rizzo
    Daniela Diverio
    Fabio Efficace
    Roberto Latagliata
    Robin Foà
    Massimo Breccia
    Annals of Hematology, 2019, 98 : 1891 - 1904
  • [33] Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
    Molica, Matteo
    Colafigli, Gioia
    Scalzulli, Emilia
    Fegatelli, Danilo Alunni
    Ranieri, Sofia Chiatamone
    Rizzo, Lorenzo
    Diverio, Daniela
    Efficace, Fabio
    Latagliata, Roberto
    Foa, Robin
    Breccia, Massimo
    ANNALS OF HEMATOLOGY, 2019, 98 (08) : 1891 - 1904
  • [34] Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
    Kockerols, Camille C. B.
    Janssen, Jeroen J. W. M.
    Blijlevens, Nicole M. A.
    Klein, Saskia K.
    van Hussen-Daenen, Laura G. M.
    van Gorkom, Gwendolyn G. Y.
    Smit, Willem M.
    van Balen, Peter
    Biemond, Bart J.
    Cruijsen, Marjan J.
    Corsten, Maarten F.
    te Boekhorst, Peter A. W.
    Koene, Harry R.
    van Sluis, Geerte L.
    Cornelissen, Jan J.
    Westerweel, Peter E.
    HAEMATOLOGICA, 2023, 108 (01) : 240 - 244
  • [35] Real-World Management of Chronic Myeloid Leukemia in Bosnia and Herzegovina: Treatment Patterns, Molecular Monitoring, and Outcomes
    Kurtovic-Kozaric, Amina
    Islamagic, Erna
    Hasic, Azra
    Mehinovic-Cavcic, Lejla
    Komic, Hana
    Kurtovic, Sabira
    BLOOD, 2022, 140 : 12218 - 12219
  • [36] Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
    Kota, Vamsi
    Maegawa, Rodrigo
    Latremouille-Viau, Dominick
    Jadhav, Kejal
    Rossi, Carmine
    Guerin, Annie
    Iorga, Serban
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S300 - S301
  • [37] Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia
    Geelen, Inge G. P.
    Thielen, Noortje
    Janssen, Jeroen J. W. M.
    Hoogendoorn, Mels
    Roosma, Tanja J. A.
    Willemsen, Sten P.
    Visser, Otto
    Cornelissen, Jan J.
    Westerweel, Peter E.
    HAEMATOLOGICA, 2017, 102 (11) : 1842 - 1849
  • [38] Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
    Eskazan, Ahmet Emre
    Keskin, Dilek
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (09) : 237 - 243
  • [39] Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
    Rudzki, Jakob
    Wolf, Dominik
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (02) : 153 - 159
  • [40] Erratum to: Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic-phase chronic myeloid leukemia
    Poe-Hirr Hsyu
    Diane R. Mould
    Richard N. Upton
    Michael Amantea
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1105 - 1106
12345